Health Care & Life Sciences » Biotechnology | Blueprint Medicines Corp.

Blueprint Medicines Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
11,400.00
27,772.00
21,426.00
44,521
Cost of Goods Sold (COGS) incl. D&A
501.00
622.00
-
-
-
-
Gross Income
501.00
622.00
-
-
-
-
SG&A Expense
20,499.00
39,112.00
62,096.00
98,767.00
171,095.00
287,303
EBIT
21,000.00
39,734.00
51,644.00
72,577.00
151,247.00
247,028
Unusual Expense
4.00
100.00
445.00
-
-
-
Non Operating Income/Expense
230.00
198.00
16.00
551.00
3,349.00
10,459
Interest Expense
138.00
453.00
696.00
469.00
221.00
73
Pretax Income
20,912.00
40,285.00
52,769.00
72,495.00
148,119.00
236,642
Consolidated Net Income
20,912.00
40,285.00
52,769.00
72,495.00
148,119.00
236,642
Net Income
20,912.00
40,285.00
52,769.00
72,495.00
148,119.00
236,642
Net Income After Extraordinaries
20,912.00
40,285.00
52,769.00
72,495.00
148,119.00
236,642
Net Income Available to Common
23,782.00
46,050.00
55,922.00
72,495.00
148,119.00
236,642
EPS (Basic)
23.43
32.41
3.07
2.64
3.92
5.39
Basic Shares Outstanding
13,083.50
13,083.50
18,235.60
27,491.70
37,792.90
43,867.40
EPS (Diluted)
1.82
3.52
3.07
2.64
3.92
5.39
Diluted Shares Outstanding
13,083.50
13,083.50
18,235.60
27,491.70
37,792.90
43,867.40
EBITDA
20,499.00
39,112.00
50,696.00
70,995.00
149,669.00
242,782
Preferred Dividends
2,870.00
5,765.00
3,153.00
-
-
-

About Blueprint Medicines

View Profile
Address
45 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.blueprintmedicines.com
Updated 07/08/2019
Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.